Frantz Viral Therapeutics focuses on developing innovative therapies that harness the power of viral vectors to treat various diseases. Their pipeline includes a range of products aimed at addressing unmet medical needs, particularly in the fields of oncology and genetic disorders. The company employs advanced viral vector technology to deliver therapeutic genes directly to target cells, enhancing the efficacy of treatments while minimizing side effects. This approach allows for precise targeting and sustained expression of therapeutic agents, which is crucial for the successful management of complex diseases.

In addition to their viral vector platform, Frantz Viral Therapeutics is committed to advancing the science of gene therapy through rigorous research and development. They utilize cutting-edge techniques to optimize the design and production of their viral vectors, ensuring high levels of safety and effectiveness. The company’s focus on scientific innovation is evident in their collaborations with leading research institutions, which aim to further explore the potential of viral therapeutics in various therapeutic areas. Through these efforts, Frantz Viral Therapeutics is positioned to make significant contributions to the field of medicine, offering hope for patients with challenging health conditions.

United States

Frantz Viral Therapeutics is focused on the development of topical treatments for pre-cancerous conditions related to human papillomavirus (HPV) infections in the cervix, vulva, and anus.

Frantz Viral Therapeutics

Company Details